Loading company…
Tokyo-based Veritas In Silico Inc. develops low molecular weight drugs that target mRNA, using AI and computational drug discovery.
Founded in 2016 and headquartered in Tokyo, Japan, Veritas In Silico Inc. works on mRNA-targeted therapies and collaborates with Takeda Pharmaceutical and Shionogi. Shingo Nakamura is founder and CEO. Its Series C round closed on December 27, 2021, raising JPY 1.4 billion (USD 10.2 mn) from investors including Global Brain and Mitsubishi UFJ Capital. Revenue in its most recent fiscal year was JPY 540,571.7 (USD 3.91 mn).
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in